RMD Stock Analysis — ResMed
Sector: Healthcare
AI Verdict
ResMed trades at 17.4x next year's earnings with 24.5% expected EPS growth, making it cheap for the growth on offer if its connected device moat keeps competitors at bay, but the overbought RSI warns of short-term pullback risk.
Competitive Moat
ResMed dominates the sleep apnea device market with a vast installed base of CPAP machines and a proprietary cloud-connected patient monitoring platform that locks in recurring software and supply revenue. Its data-driven ecosystem creates switching costs for both patients and providers, making it hard for competitors to dislodge.
Summary
ResMed is notable for its cloud-connected CPAP devices and software ecosystem that generate recurring revenue streams.
Where It Stands
Despite a 1-year return of -21.60%, ResMed trades at 17.4x forward earnings—below the healthcare sector median of 22x—while its RSI of 74.5 signals overbought conditions after a sharp rebound.
Key Metrics
- RSI: 74.5 — Overbought
- Trailing P/E: 21.7x
- Forward P/E: 17.4x
- PEG Ratio: 0.91
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $32.8B
- Dividend Yield: 0.01%
- 1-Year Return: -21.60%
- 52-Week High: $293.81
- 52-Week Low: $180.26
Analyst Consensus
12 Buy · 11 Hold · 2 Sell (25 analysts)
Bull Case
With analysts forecasting 24.5% EPS growth and a forward P/E of 17.4x, you're paying a low price for above-average earnings acceleration if ResMed's device and data moat holds.
Bear Case
An RSI of 74.5 means the stock is overbought, so even a modest pullback to a neutral RSI could erase recent gains, especially given last year's -21.60% return.
Catalyst to Watch
Watch for regulatory or reimbursement decisions on sleep apnea treatments—positive clarity could reinforce earnings growth, while negative surprises could pressure the multiple.